Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
Q9BTE6
UPID:
AASD1_HUMAN
Alternative names:
Alanyl-tRNA synthetase domain-containing protein 1
Alternative UPACC:
Q9BTE6; B4DI73
Background:
Alanyl-tRNA editing protein Aarsd1, also known as Alanyl-tRNA synthetase domain-containing protein 1, plays a crucial role in protein synthesis. It functions in trans to correct the amino acid moiety from incorrectly charged tRNA(Ala), ensuring the accuracy of protein translation. This process is vital for the proper functioning of cellular machinery.
Therapeutic significance:
Understanding the role of Alanyl-tRNA editing protein Aarsd1 could open doors to potential therapeutic strategies. Its precise function in amino acid correction highlights its importance in maintaining protein integrity, suggesting that modulation of its activity could have implications in diseases where protein synthesis is compromised.